LABOR. FARMAC. ROVI
LABOR. FARMAC. ROVI operates in Diversified Metals & Mining.
LABOR. FARMAC. ROVI (41L) - Net Assets
Latest net assets as of June 2024: €482.76 Million EUR
Based on the latest financial reports, LABOR. FARMAC. ROVI (41L) has net assets worth €482.76 Million EUR as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€857.33 Million) and total liabilities (€374.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €482.76 Million |
| % of Total Assets | 56.31% |
| Annual Growth Rate | 16.79% |
| 5-Year Change | 68.58% |
| 10-Year Change | N/A |
| Growth Volatility | 14.87 |
LABOR. FARMAC. ROVI - Net Assets Trend (2016–2023)
This chart illustrates how LABOR. FARMAC. ROVI's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LABOR. FARMAC. ROVI (2016–2023)
The table below shows the annual net assets of LABOR. FARMAC. ROVI from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €543.49 Million | +4.24% |
| 2022-12-31 | €521.38 Million | +10.70% |
| 2021-12-31 | €470.98 Million | +26.03% |
| 2020-12-31 | €373.70 Million | +15.92% |
| 2019-12-31 | €322.39 Million | +12.15% |
| 2018-12-31 | €287.47 Million | +49.97% |
| 2017-12-31 | €191.69 Million | +4.52% |
| 2016-12-31 | €183.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LABOR. FARMAC. ROVI's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 194.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €555.53 Million | 102.99% |
| Total Equity | €539.39 Million | 100.00% |
LABOR. FARMAC. ROVI Competitors by Market Cap
The table below lists competitors of LABOR. FARMAC. ROVI ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Invesco Physical Bitcoin ETN EUR
XETRA:BTIC
|
$608.85K |
|
Enertopia Corporatio
OTCQB:ENRT
|
$609.29K |
|
INCUVO S.A. ZY -50
F:68X
|
$609.79K |
|
Alumindo Light Metal Industry
JK:ALMI
|
$610.80K |
|
Financiere Hoche Bains-Les-Bains SA
PA:MLHBB
|
$608.00K |
|
PBS Finanse SA
WAR:PBF
|
$608.00K |
|
HEINEKEN HOLDING (4H5.SG)
STU:4H5
|
$607.63K |
|
Aranjin Resources Ltd
V:ARJN
|
$607.03K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LABOR. FARMAC. ROVI's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 520,012,000 to 539,387,000, a change of 19,375,000 (3.7%).
- Net income of 170,335,000 contributed positively to equity growth.
- Dividend payments of 69,049,000 reduced retained earnings.
- Share repurchases of 133,900,000 reduced equity.
- New share issuances of 52,639,000 increased equity.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €170.34 Million | +31.58% |
| Dividends Paid | €69.05 Million | -12.8% |
| Share Repurchases | €133.90 Million | -24.82% |
| Share Issuances | €52.64 Million | +9.76% |
| Other Changes | €-650.00K | -0.12% |
| Total Change | €- | 3.73% |
Book Value vs Market Value Analysis
This analysis compares LABOR. FARMAC. ROVI's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.03x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 16.16x to 6.03x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €3.89 | €62.80 | x |
| 2018-12-31 | €5.19 | €62.80 | x |
| 2019-12-31 | €5.82 | €62.80 | x |
| 2020-12-31 | €6.75 | €62.80 | x |
| 2021-12-31 | €8.59 | €62.80 | x |
| 2022-12-31 | €9.93 | €62.80 | x |
| 2023-12-31 | €10.41 | €62.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LABOR. FARMAC. ROVI utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 31.58%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.53%
- • Asset Turnover: 1.04x
- • Equity Multiplier: 1.48x
- Recent ROE (31.58%) is above the historical average (20.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 14.22% | 9.84% | 0.92x | 1.57x | €7.75 Million |
| 2017 | 8.99% | 6.25% | 0.92x | 1.56x | €-1.93 Million |
| 2018 | 6.22% | 5.90% | 0.75x | 1.40x | €-10.85 Million |
| 2019 | 12.18% | 10.30% | 0.75x | 1.59x | €7.03 Million |
| 2020 | 16.34% | 14.54% | 0.73x | 1.54x | €23.69 Million |
| 2021 | 32.50% | 23.60% | 0.89x | 1.56x | €105.98 Million |
| 2022 | 38.40% | 24.42% | 0.93x | 1.69x | €147.67 Million |
| 2023 | 31.58% | 20.53% | 1.04x | 1.48x | €116.40 Million |
Industry Comparison
This section compares LABOR. FARMAC. ROVI's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LABOR. FARMAC. ROVI (41L) | €482.76 Million | 14.22% | 0.78x | $608.65K |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |